Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

The University of Chicago Medicine Comprehensive Cancer Center

5841 South Maryland Avenue, Chicago, IL 60637

The University of Chicago Medicine Comprehensive Cancer Center, located in Chicago’s Hyde Park neighborhood, is committed to exploring and developing innovative ways to prevent and reduce cancer’s devastating effects through a collaborative research program involving more than 200 renowned researchers and physicians. UChicago’s Comprehensive Cancer Center is one of only two NCI-designated Comprehensive Cancer Centers in Illinois and has earned a reputation for excellence, innovation, and a commitment to addressing cancer from every angle.

Seminal discoveries made at UChicago have stimulated the development and introduction of many of the cancer treatments used today. Many of the roots of chemotherapy, hormonal therapy, gene therapy, and bone marrow transplantation can be traced to UChicago. For example, Dr. Janet D. Rowley made many breakthroughs vital to understanding the relationships between genetics and cancer, and opened the door to effective targeted therapies for leukemias and lymphomas.

This legacy of discovery drives our researchers to pursue breakthroughs that will lead to new and better cancer treatments. Together, we can #AnswerCancer.

Website: The University of Chicago Medicine Comprehensive Cancer Center

Contact:
Amanda Spratt
773-834-4031

Trials at this location:

BRE12-158

A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer.

Status: Open to Accrual
Read More

GU15-217

Study Title: UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch: Hoosier Cancer Research Network GU15-217

Status: Open to Accrual
Read More

TBCRC035

Palbociclib in Combination with Fulvestrant or Tamoxifen as Treatment for Hormone Receptor Positive Metastatic Breast Cancer with Prior Chemotherapy for Advanced Disease: A Phase II study with Pharmacodynamics Markers (TBCRC035)

Status: Open to Accrual
Read More